Zogenix Inc: (NASD: ZGNX)

$1.61

0.01 (0.63%)

Volume 128,777

May 20 11:29 AM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		1.60 - 1.64
	
		52wk Low - High
		1.11 - 3.30
	
		Previous Close
		1.60
	
		Avg. Volume
		763,012
	
		Industry
		MED-DRUGS
	
		Market Cap
		161.29 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.66
	
		PE (Forward)
		0.00
	
		Current Year Est.
		-0.61
	
		Quarterly Earnings ESP 
		-7.14%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		88 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/9/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -0.61
                        
                            Current Quarter Estimate
                            -0.14
                        
                            Most Accurate Estimate
                            -0.15
                        
                            Earnings ESP 
                            -7.14%
                        
                            Next Earnings Report Date
                            08-07-2013
                        
                            EPS Last Year
                            -0.74
                        
                            Expected Earnings Growth
                            25.00%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel? DosePro? is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA.   
Full ZGNX Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
ZGNX Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.14	-0.14	-0.61	-0.36
Number of Estimates	5	5	5	5
Low Estimate	-0.17	-0.15	-0.67	-0.52
High Estimate	-0.13	-0.12	-0.53	NA
Year Ago EPS	-0.26	-0.15	-0.72	-0.61
EPS Growth	44.62%	9.33%	15.00%	40.85%

More ZGNX Estimates

Average Earnings Estimates for ZGNX

EPS Growth for ZGNX

Industry Analysis

Name	Symbol	Previous Close
ZOGENIX INC	ZGNX	1.60
JAZZ PHARMACEUT	JAZZ	58.36
SALIX PHARM-LTD	SLXP	59.28
SANTARUS INC	SNTS	21.91
USANA HLTH SCI	USNA	65.46
BIOCRYST PHARMA	BCRX	1.71
CATALYST PHARMA	CPRX	0.83
CELL THERAPEUT	CTIC	1.16
CUBIST PHARM	CBST	49.51
ELAN CP PLC ADR	ELN	11.67

Sector:Medical>> Industry:MED-DRUGS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Loss Narrows at Zogenix

Mar 18, 2013

Mixed 3Q for Covidien, Profit Drops

Jul 26, 2012

Earnings Preview: Covidien

Jul 23, 2012

Covidien Promotes Zogenix's Product

Jun 08, 2012

Report for ZGNX

May 09, 2013

More ZGNX Zacks Commentary

Financials

EPS TTM	-0.74
Sales	44
Net Income	-58
Price/Earnings	NA
Price/Book	11.13
Price/Cash Flow	NA
Price/Sales	4.89

More ZGNX Financials

News

Aradigm Reports First Quarter 2013 Financial Results - Close-Up Media

May 16, 2013

Zogenix announces positive results from extended Phase I schizophrenia trial - Datamonitor

May 16, 2013

Aradigm Announces First Quarter 2013 Financial Results - Businesswire

May 14, 2013

Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin - TheStreet.com

May 10, 2013

Zogenix Reports First Quarter 2013 Financial Results - Globenewswire

May 9, 2013

AERL, ZGNX, NPTN Expected To Be Down After Next Earnings Releases - M2

May 8, 2013

Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 - M2

May 8, 2013

Plunkett's Companion to The Almanac of American Employers 2013: Market Research, Statistics & Trends Pertaining to America's Hottest Mid-size Employers - M2

May 8, 2013

See All News Stories on ZGNX

Broker Recommendations

Current ABR	1.67
ABR (Last Week)	1.67
# of recs in ABR	6
Average Target Price	3.67
Industry Rank by ABR	88 out of 265
Rank in Industry	17 out of 91

More ZGNX Broker Recommendations

Username: Password:

Remember me [?]

Forgot Password

New Member

Zogenix Inc: (NASD: ZGNX)

$1.61

0.01 (0.63%)

Volume 128,777

May 20 11:29 AM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks #1 Rank Strong Buys

Zacks Recommendation Long-Term: 6+ Months

All Outperform Rated Stocks

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-DRUGS

Zacks Commentary

Loss Narrows at Zogenix

Mixed 3Q for Covidien, Profit Drops

Earnings Preview: Covidien

Covidien Promotes Zogenix's Product

Report for ZGNX

Financials

News

Aradigm Reports First Quarter 2013 Financial Results - Close-Up Media

Zogenix announces positive results from extended Phase I schizophrenia trial - Datamonitor

Aradigm Announces First Quarter 2013 Financial Results - Businesswire

Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin - TheStreet.com

Zogenix Reports First Quarter 2013 Financial Results - Globenewswire

AERL, ZGNX, NPTN Expected To Be Down After Next Earnings Releases - M2

Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 - M2

Plunkett's Companion to The Almanac of American Employers 2013: Market Research, Statistics & Trends Pertaining to America's Hottest Mid-size Employers - M2

Broker Recommendations

Day Low - High	1.60 - 1.64
52wk Low - High	1.11 - 3.30
Previous Close	1.60
Avg. Volume	763,012
Industry	MED-DRUGS
Market Cap	161.29 M
Div - Yield	0.00 - 0.00
Beta	0.66
PE (Forward)	0.00
Current Year Est.	-0.61
Quarterly Earnings ESP	-7.14%

PE (Forward)	NA
PEG Ratio	NA
Current Year Est.	-0.61
Current Quarter Estimate	-0.14
Most Accurate Estimate	-0.15
Earnings ESP	-7.14%
Next Earnings Report Date	08-07-2013
EPS Last Year	-0.74
Expected Earnings Growth	25.00%